Filing Details

Accession Number:
0000899243-19-013252
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-13 17:00:58
Reporting Period:
2019-05-09
Accepted Time:
2019-05-13 17:00:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1563880 Trevi Therapeutics Inc. TRVI Pharmaceutical Preparations (2834) 450834299
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1774767 Foundation Mellon King Richard C/O Trevi Therapeutics, Inc.
195 Church Street, 14Th Floor
New Haven CT 06510
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-09 222,816 $0.00 222,816 No 4 C Direct
Common Stock Acquisiton 2019-05-09 24,341 $0.00 247,157 No 4 J Direct
Common Stock Acquisiton 2019-05-09 100,000 $10.00 347,157 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 J Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Preferred Stock Disposition 2019-05-09 1,908,450 $0.00 222,816 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
Footnotes
  1. On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. Consists of shares transferred to Richard King Mellon Foundation by TPG Biotechnology Partners III, L.P. in connection with the closing of the Issuer's initial public offering.